Diagnostic Utility of CD10, EMA and BCL2 Markers in Differentiating Between Squamous Cell Carcinoma and Basal Cell Carcinoma of Skin

Authors

  • Shafaq Khadija Department of Pathology, Fazaia Medical College Islamabad
  • Manal Rauf Department of Pathology , Pakistan Institute of Medical Sciences Islamabad, Pakistan
  • Misha Anis Department of Pathology , Pakistan Institute of Medical Sciences Islamabad, Pakistan
  • Armaghana Qamar Khan Department of Pathology , Pakistan Institute of Medical Sciences Islamabad, Pakistan
  • Sumaiya Shahab Department of Pathology , Pakistan Institute of Medical Sciences Islamabad, Pakistan
  • Ahmardeen Khalid Department of Pathology , Pakistan Institute of Medical Sciences Islamabad, Pakistan

Keywords:

basal cell carcinoma, squamous cell carcinoma, CD10, EMA, Bcl2

Abstract

Introduction: Non Melanocytic Skin Cell Carcinomas are the commonest malignancies among  aucasians.

According to a study conducted 59.5% BCC cases showed CD10 positivity whereas 100% SCC cases showed negativity. Expression of Bcl-2 found positive in 96.5% of BCC cases and 100% negative in SCC. Studies demonstrate EMA to be positive in 100% cases of SCC while showing 100% negativity for BCC. Differentiating BCC from SCC on the basis of IHC is vital as both have diverse managements based on their different prognosis, metastasis and recurrence.

Objectives: To study expression of CD10, BcL2 and EMA in BCC and SCC and correlate this expression in

differentiating between BCC and SCC.

Methods: Study had 64 samples taken from 1st September 2018 - 31st August 2019 at department of

Histopathology, PIMS, SZABMU, and Islamabad. After H&E staining, IHC was done with CD 10, EMA and Bcl 2 markers and the results evaluated.

Results: CD10 showed positivity in 81.6% of BCC cases and negativity in 84.8% cases of the SCC. Bcl2

immunoreactivity was seen in 84.4% BCC cases whereas SCC showed negativity in 84.9% cases. Considering immune-expression of EMA in SCC 90.6% cases showed positive staining; only 9.4% cases were negative for EMA. 96.9% cases of BCC were negative for EMA.

Conclusion: We suggest that concurrent application of CD10, BCL2 and EMA Immuno markers has high

diagnostic value where distinction between BCC and SCC cannot be made on routine microscopy.

Downloads

Published

2022-02-09

Issue

Section

Original article

How to Cite

1.
Khadija S. Diagnostic Utility of CD10, EMA and BCL2 Markers in Differentiating Between Squamous Cell Carcinoma and Basal Cell Carcinoma of Skin. Int J Pathol [Internet]. 2022 Feb. 9 [cited 2024 Jul. 23];19(3):121-7. Available from: https://jpathology.com/index.php/OJS/article/view/679

Most read articles by the same author(s)

1 2 > >>